Article Text

Download PDFPDF

COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study
Free
  1. Muserref Kasap Cuceoglu,
  2. Ezgi Deniz Batu,
  3. Yelda Bilginer,
  4. Seza Özen
  1. Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  1. Correspondence to Seza Özen, Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey; sezaozen{at}hacettepe.edu.tr

Statistics from Altmetric.com

We read with great interest the article by Salvarani et al comparing the COVID-19 infection susceptibility and severity between the patients treated with biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) and all residents in the Reggio Emilia area.1 In their cohort of 1195 patients treated with b/tsDMARDs, there were nine confirmed COVID-19 cases. None of these COVID-19 cases were ≤45 years of age while only two out of 25 patients who were tested for COVID-19 were ≤45 years. They did not observe a different susceptibility or severity of COVID-19 in patients treated with these drugs.1

Biologic/targeted synthetic DMARDs often target pathways of the immune system and this may result in a tendency for infections.2 Serious infections have been reported in both children and adults treated with these drugs.3 However, the data about infection rate and severity in children on b/ts DMARDs are limited. Consistent …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles